Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.

Maurya, S; Srivastava, R; Arfin, S; Hawthorne, S; Jha, NK; Agrawal, K; Raj, S; Rathi, B; Kumar, A; Raj, R; Agrawal, S; Paiva-Santos, AC; Malik, AA; Dua, K; Rana, R; Ojha, S; Jha, SK; Sharma, A; Kumar, D; El-Zahaby, SA; Nagar, A

Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.

Maurya, S Srivastava, R Arfin, S Hawthorne, S Jha, NK Agrawal, K Raj, S Rathi, B Kumar, A Raj, R Agrawal, S Paiva-Santos, AC Malik, AA Dua, K

Rana, R Ojha, S Jha, SK Sharma, A Kumar, D El-Zahaby, SA Nagar, A

Permalink

Publisher:: Future Medicine Ltd
Publication Type:: Journal Article
Citation:: Nanomedicine (Lond), 2023
Issue Date:: 2023-03-28

Closed Access

	Filename	Description	Size
	Future medicine nnm-2021-0437.pdf	Published version	4.18 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Maurya, S
dc.contributor.author	Srivastava, R
dc.contributor.author	Arfin, S
dc.contributor.author	Hawthorne, S
dc.contributor.author	Jha, NK
dc.contributor.author	Agrawal, K
dc.contributor.author	Raj, S
dc.contributor.author	Rathi, B
dc.contributor.author	Kumar, A
dc.contributor.author	Raj, R
dc.contributor.author	Agrawal, S
dc.contributor.author	Paiva-Santos, AC
dc.contributor.author	Malik, AA
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Rana, R
dc.contributor.author	Ojha, S
dc.contributor.author	Jha, SK
dc.contributor.author	Sharma, A
dc.contributor.author	Kumar, D
dc.contributor.author	El-Zahaby, SA
dc.contributor.author	Nagar, A
dc.date.accessioned	2023-03-30T19:03:30Z
dc.date.available	2023-03-30T19:03:30Z
dc.date.issued	2023-03-28
dc.identifier.citation	Nanomedicine (Lond), 2023
dc.identifier.issn	1743-5889
dc.identifier.issn	1748-6963
dc.identifier.uri	http://hdl.handle.net/10453/168891
dc.description.abstract	Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.
dc.language	eng
dc.publisher	Future Medicine Ltd
dc.relation.ispartof	Nanomedicine (Lond)
dc.relation.isbasedon	10.2217/nnm-2021-0437
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0306 Physical Chemistry (incl. Structural), 1004 Medical Biotechnology, 1007 Nanotechnology
dc.subject.classification	Nanoscience & Nanotechnology
dc.title	Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	0306 Physical Chemistry (incl. Structural)
utslib.for	1004 Medical Biotechnology
utslib.for	1007 Nanotechnology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2023-03-30T19:03:28Z
pubs.publication-status	Published online

Abstract:

Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/168891